Overview

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Status:
Completed

Trial end date:
2022-05-09

Target enrollment:

Participant gender:

Summary

Study to evaluate the efficacy and safety of Buspirone, sustained-release tablets, 15 mg in patients with autonomic dysfunction syndrome accompanied by vertigo

Phase:

Phase 3

Details

Lead Sponsor:

Valenta Pharm JSC

Treatments:

Buspirone